Global Hospital acquired infections therapeutic Market Size study, by Infection Type (Urinary Tract Infections, Ventilator Associated Pneumonia, Surgical Site Infections, Bloodstream Infections), by Drug Class (Antibacterial Drugs, Antiviral Drugs, Antifungal Drugs) and Regional Forecasts 2021-2027

BIZ4595033
200 Pages
June 2021
Pharmaceuticals

Download Sample Get Discount

Global Hospital acquired infections therapeutic Market is valued approximately USD 10.54 billion in 2020 and is anticipated to grow with a healthy growth rate of more than 2.3 % over the forecast period 2021-2027. Hospital acquired infections is antifungal therapy which are added to empiric antibiotic coverage. Antiviral therapy can be used in the treatment of suspected disseminated viral infections. Rise in approval and launch of new drugs, increasing hospitalization due to rising burden of chronic diseases has led the adoption of Hospital acquired infections therapeutic across the forecast period. As rising population need large number of services which enforces rising in hospitalization due to chronic diseases. For Instance: As per the WHO in 2019, there were almost 17.9 million deaths from all types of cardiovascular diseases all over the world. This statistic describes the number of deaths caused by selected chronic diseases worldwide in 2019. However, declining demand for HAI drugs impedes the growth of the market over the forecast period of 2021-2027. Also, with the High prevalence of HAIs, is responsible to increase the market growth during the forecast period.

Global Hospital acquired infections therapeutic Market is segmented on the basis of geographical reason as Asia Pacific, North America, Europe, Latin America and Rest of the World. As far as the geographical region concerned, North America is deemed as leader of market and witnessed robust growth owing to growing non-invasive surgeries, adequate health infrastructure. Whereas, Asia-Pacific is coming up as one of the promising regions as huge market growth is observed due to factors such as rising population, growing health infrastructure would create profitable growth prospects for the Hospital acquired infections therapeutic Market across Asia-Pacific region

Major market player included in this report are:

Pfizer Inc.

MERCK & CO., Inc.

Bayer AG

GlaxoSmithKline

Daiichi Sankyo Company, Limited

AbbVie Inc.

Basilea Pharmaceutica AG

Abbott Inc.

F. Hoffmann-La Roche Ltd

Allergan Plc.

The objective of the study is to define market sizes of different segments & countries in recent years and to forecast the values to the coming eight years. The report is designed to incorporate both qualitative and quantitative aspects of the industry within each of the regions and countries involved in the study. Furthermore, the report also caters the detailed information about the crucial aspects such as driving factors & challenges which will define the future growth of the market. Additionally, the report shall also incorporate available opportunities in micro markets for stakeholders to invest along with the detailed analysis of competitive landscape and product offerings of key players. The detailed segments and sub-segment of the market are explained below:

Urinary Tract Infections

Ventilator Associated Pneumonia

Surgical Site Infections

Bloodstream Infections

Others

By Drug Class:

Antibacterial Drugs

Antiviral Drugs

Antifungal Drugs

By Region:

North America

U.S.

Canada

Europe

Germany

France

Spain

Italy

ROE

Asia Pacific

China

India

Japan

Australia

South Korea

RoAPAC

Latin America

Brazil

Mexico

Rest of the World

Furthermore, years considered for the study are as follows:

Historical year – 2018, 2019

Base year – 2020

Forecast period – 2021 to 2027

Target Audience of the Global Hospital acquired infections therapeutic Market in Market Study:

Key Consulting Companies & Advisors

Large, medium-sized, and small enterprises

Venture capitalists

Value-Added Resellers (VARs)

Third-party knowledge providers

Investment bankers

Investors

Chapter 1. Executive Summary

1.1. Market Snapshot

1.2. Global & Segmental Market Estimates & Forecasts, 2019-2027 (USD Billion)

1.2.1. Hospital acquired infections therapeutic Market, by region, 2019-2027 (USD Billion)

1.2.2. Hospital acquired infections therapeutic Market, by Infection Type, 2019-2027 (USD Billion)

1.2.3. Hospital acquired infections therapeutic Market, by Drug Class, 2019-2027 (USD Billion)

1.3. Key Trends

1.4. Estimation Methodology

1.5. Research Assumption

Chapter 2. Global Hospital acquired infections therapeutic Market Definition and Scope

2.1. Objective of the Study

2.2. Market Definition & Scope

2.2.1. Scope of the Study

2.2.2. Industry Evolution

2.3. Years Considered for the Study

2.4. Currency Conversion Rates

Chapter 3. Global Hospital acquired infections therapeutic Market Dynamics

3.1. Hospital acquired infections therapeutic Market Impact Analysis (2019-2027)

3.1.1. Market Drivers

3.1.1.1. Rise in approval and launch of new drugs

3.1.1.2. Increasing hospitalization due to rising burden of chronic diseases

3.1.2. Market Challenges

3.1.2.1. Declining demand for HAI drugs

3.1.3. Market Opportunities

3.1.3.1. High prevalence of HAIs

Chapter 4. Global Hospital acquired infections therapeutic Market Industry Analysis

4.1. Porter’s 5 Force Model

4.1.1. Bargaining Power of Suppliers

4.1.2. Bargaining Power of Buyers

4.1.3. Threat of New Entrants

4.1.4. Threat of Substitutes

4.1.5. Competitive Rivalry

4.1.6. Futuristic Approach to Porter’s 5 Force Model (2018-2027)

4.2. PEST Analysis

4.2.1. Political

4.2.2. Economical

4.2.3. Social

4.2.4. Technological

4.3. Investment Adoption Model

4.4. Analyst Recommendation & Conclusion

Chapter 5. Global Hospital acquired infections therapeutic Market, by Infection Type

5.1. Market Snapshot

5.2. Global Hospital acquired infections therapeutic Market by Infection Type, Performance - Potential Analysis

5.3. Global Hospital acquired infections therapeutic Market Estimates & Forecasts by Infection Type 2018-2027 (USD Billion)

5.4. Hospital acquired infections therapeutic Market, Sub Segment Analysis

5.4.1. Urinary Tract Infections

5.4.2. Ventilator Associated Pneumonia

5.4.3. Surgical Site Infections

5.4.4. Bloodstream Infections

5.4.5. Others

Chapter 6. Global Hospital acquired infections therapeutic Market, by Drug Class

6.1. Market Snapshot

6.2. Global Hospital acquired infections therapeutic Market by Drug Class, Performance - Potential Analysis

6.3. Global Hospital acquired infections therapeutic Market Estimates & Forecasts by Drug Class 2018-2027 (USD Billion)

6.4. Hospital acquired infections therapeutic Market, Sub Segment Analysis

6.4.1. Antibacterial Drugs

6.4.2. Antiviral Drugs

6.4.3. Antifungal Drugs

Chapter 7. Global Hospital acquired infections therapeutic Market, Regional Analysis

7.1. Hospital acquired infections therapeutic Market, Regional Market Snapshot

7.2. North America Hospital acquired infections therapeutic Market

7.2.1. U.S. Hospital acquired infections therapeutic Market

7.2.1.1. Infection Type breakdown estimates & forecasts, 2018-2027

7.2.2. Canada Hospital acquired infections therapeutic Market

7.3. Europe Hospital acquired infections therapeutic Market Snapshot

7.3.1. U.K. Hospital acquired infections therapeutic Market

7.3.2. Germany Hospital acquired infections therapeutic Market

7.3.3. France Hospital acquired infections therapeutic Market

7.3.4. Spain Hospital acquired infections therapeutic Market

7.3.5. Italy Hospital acquired infections therapeutic Market

7.3.6. Rest of Europe Hospital acquired infections therapeutic Market

7.4. Asia-Pacific Hospital acquired infections therapeutic Market Snapshot

7.4.1. China Hospital acquired infections therapeutic Market

7.4.2. India Hospital acquired infections therapeutic Market

7.4.3. Japan Hospital acquired infections therapeutic Market

7.4.4. Australia Hospital acquired infections therapeutic Market

7.4.5. South Korea Hospital acquired infections therapeutic Market

7.4.6. Rest of Asia Pacific Hospital acquired infections therapeutic Market

7.5. Latin America Hospital acquired infections therapeutic Market Snapshot

7.5.1. Brazil Hospital acquired infections therapeutic Market

7.5.2. Mexico Hospital acquired infections therapeutic Market

7.6. Rest of The World Hospital acquired infections therapeutic Market

Chapter 8. Competitive Intelligence

8.1. Top Market Strategies

8.2. Company Profiles

8.2.1. Pfizer Inc.

8.2.1.1. Key Information

8.2.1.2. Overview

8.2.1.3. Financial (Subject to Data Availability)

8.2.1.4. Infection Summary

8.2.1.5. Recent Developments

8.2.2. MERCK & CO., Inc.

8.2.3. Bayer AG

8.2.4. GlaxoSmithKline

8.2.5. Daiichi Sankyo Company, Limited

8.2.6. AbbVie Inc.

8.2.7. Basilea Pharmaceutica AG

8.2.8. Abbott Inc.

8.2.9. F. Hoffmann-La Roche Ltd

8.2.10. Allergan Plc.

Chapter 9. Research Process

9.1. Research Process

9.1.1. Data Mining

9.1.2. Analysis

9.1.3. Market Estimation

9.1.4. Validation

9.1.5. Publishing

9.2. Research Attributes

9.3. Research Assumption

List of Tables

TABLE 1. Global Hospital acquired infections therapeutic market, report scope

TABLE 2. Global Hospital acquired infections therapeutic market estimates & forecasts by Region 2018-2027 (USD Billion)

TABLE 3. Global Hospital acquired infections therapeutic market estimates & forecasts by Infection Type 2018-2027 (USD Billion)

TABLE 4. Global Hospital acquired infections therapeutic market by segment, estimates & forecasts, 2018-2027 (USD Billion)

TABLE 5. Global Hospital acquired infections therapeutic market by region, estimates & forecasts, 2018-2027 (USD Billion)

TABLE 6. Global Hospital acquired infections therapeutic market by segment, estimates & forecasts, 2018-2027 (USD Billion)

TABLE 7. Global Hospital acquired infections therapeutic market by region, estimates & forecasts, 2018-2027 (USD Billion)

TABLE 8. Global Hospital acquired infections therapeutic market by segment, estimates & forecasts, 2018-2027 (USD Billion)

TABLE 9. Global Hospital acquired infections therapeutic market by region, estimates & forecasts, 2018-2027 (USD Billion)

TABLE 10. Global Hospital acquired infections therapeutic market by segment, estimates & forecasts, 2018-2027 (USD Billion)

TABLE 11. Global Hospital acquired infections therapeutic market by region, estimates & forecasts, 2018-2027 (USD Billion)

TABLE 12. Global Hospital acquired infections therapeutic market by segment, estimates & forecasts, 2018-2027 (USD Billion)

TABLE 13. Global Hospital acquired infections therapeutic market by region, estimates & forecasts, 2018-2027 (USD Billion)

TABLE 14. U.S. Hospital acquired infections therapeutic market estimates & forecasts, 2018-2027 (USD Billion)

TABLE 15. U.S. Hospital acquired infections therapeutic market estimates & forecasts by segment 2018-2027 (USD Billion)

TABLE 16. U.S. Hospital acquired infections therapeutic market estimates & forecasts by segment 2018-2027 (USD Billion)

TABLE 17. Canada Hospital acquired infections therapeutic market estimates & forecasts, 2018-2027 (USD Billion)

TABLE 18. Canada Hospital acquired infections therapeutic market estimates & forecasts by segment 2018-2027 (USD Billion)

TABLE 19. Canada Hospital acquired infections therapeutic market estimates & forecasts by segment 2018-2027 (USD Billion)

TABLE 20. UK Hospital acquired infections therapeutic market estimates & forecasts, 2018-2027 (USD Billion)

TABLE 21. UK Hospital acquired infections therapeutic market estimates & forecasts by segment 2018-2027 (USD Billion)

TABLE 22. UK Hospital acquired infections therapeutic market estimates & forecasts by segment 2018-2027 (USD Billion)

TABLE 23. Germany Hospital acquired infections therapeutic market estimates & forecasts, 2018-2027 (USD Billion)

TABLE 24. Germany Hospital acquired infections therapeutic market estimates & forecasts by segment 2018-2027 (USD Billion)

TABLE 25. Germany Hospital acquired infections therapeutic market estimates & forecasts by segment 2018-2027 (USD Billion)

TABLE 26. RoE Hospital acquired infections therapeutic market estimates & forecasts, 2018-2027 (USD Billion)

TABLE 27. RoE Hospital acquired infections therapeutic market estimates & forecasts by segment 2018-2027 (USD Billion)

TABLE 28. RoE Hospital acquired infections therapeutic market estimates & forecasts by segment 2018-2027 (USD Billion)

TABLE 29. China Hospital acquired infections therapeutic market estimates & forecasts, 2018-2027 (USD Billion)

TABLE 30. China Hospital acquired infections therapeutic market estimates & forecasts by segment 2018-2027 (USD Billion)

TABLE 31. China Hospital acquired infections therapeutic market estimates & forecasts by segment 2018-2027 (USD Billion)

TABLE 32. India Hospital acquired infections therapeutic market estimates & forecasts, 2018-2027 (USD Billion)

TABLE 33. India Hospital acquired infections therapeutic market estimates & forecasts by segment 2018-2027 (USD Billion)

TABLE 34. India Hospital acquired infections therapeutic market estimates & forecasts by segment 2018-2027 (USD Billion)

TABLE 35. Japan Hospital acquired infections therapeutic market estimates & forecasts, 2018-2027 (USD Billion)

TABLE 36. Japan Hospital acquired infections therapeutic market estimates & forecasts by segment 2018-2027 (USD Billion)

TABLE 37. Japan Hospital acquired infections therapeutic market estimates & forecasts by segment 2018-2027 (USD Billion)

TABLE 38. RoAPAC Hospital acquired infections therapeutic market estimates & forecasts, 2018-2027 (USD Billion)

TABLE 39. RoAPAC Hospital acquired infections therapeutic market estimates & forecasts by segment 2018-2027 (USD Billion)

TABLE 40. RoAPAC Hospital acquired infections therapeutic market estimates & forecasts by segment 2018-2027 (USD Billion)

TABLE 41. Brazil Hospital acquired infections therapeutic market estimates & forecasts, 2018-2027 (USD Billion)

TABLE 42. Brazil Hospital acquired infections therapeutic market estimates & forecasts by segment 2018-2027 (USD Billion)

TABLE 43. Brazil Hospital acquired infections therapeutic market estimates & forecasts by segment 2018-2027 (USD Billion)

TABLE 44. Mexico Hospital acquired infections therapeutic market estimates & forecasts, 2018-2027 (USD Billion)

TABLE 45. Mexico Hospital acquired infections therapeutic market estimates & forecasts by segment 2018-2027 (USD Billion)

TABLE 46. Mexico Hospital acquired infections therapeutic market estimates & forecasts by segment 2018-2027 (USD Billion)

TABLE 47. RoLA Hospital acquired infections therapeutic market estimates & forecasts, 2018-2027 (USD Billion)

TABLE 48. RoLA Hospital acquired infections therapeutic market estimates & forecasts by segment 2018-2027 (USD Billion)

TABLE 49. RoLA Hospital acquired infections therapeutic market estimates & forecasts by segment 2018-2027 (USD Billion)

TABLE 50. Row Hospital acquired infections therapeutic market estimates & forecasts, 2018-2027 (USD Billion)

TABLE 51. Row Hospital acquired infections therapeutic market estimates & forecasts by segment 2018-2027 (USD Billion)

TABLE 52. Row Hospital acquired infections therapeutic market estimates & forecasts by segment 2018-2027 (USD Billion)

TABLE 53. List of secondary sources, used in the study of global Hospital acquired infections therapeutic market

TABLE 54. List of primary sources, used in the study of global Hospital acquired infections therapeutic market

TABLE 55. Years considered for the study

TABLE 56. Exchange rates considered

Purchase Options

* Taxes/Fees, If applicable will be
added during checkout. All prices in USD.

Need More Information

Contact Us

+ 1-888-961-4454

Drop Us an email at

help@bigmarketresearch.com

Global Hospital acquired infections therapeutic Market Size study, by Infection Type (Urinary Tract Infections, Ventilator Associated Pneumonia, Surgical Site Infections, Bloodstream Infections), by Drug Class (Antibacterial Drugs, Antiviral Drugs, Antifungal Drugs) and Regional Forecasts 2021-2027

Contact Us

Drop Us an email at

Similar Reports

Client Testimonials

Maria

David

Sara